Posts tagged VKTX
Viking reports positive POC study in X-ALD

Viking Therapeutics (NASDAQ:VKTX) announced positive top-line results from a proof-of-concept study of VK0214 in a mouse model of X-linked adrenoleukodystrophy (X-ALD).

The results showed that VK0214 rapidly reduced very long chain fatty acid (VLCFA) levels in plasma by more than 25% in treated animals, compared with vehicle controls.  The study successfully achieved its primary objective, which was to demonstrate the ability of VK0214 to lower plasma VLCFA levels after six weeks of treatment.

Read More